Laekna (2105) Stock Overview
An investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis in the People’s Republic of China, the United States of America, and South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
2105 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Laekna, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$15.95 |
| 52 Week High | HK$23.50 |
| 52 Week Low | HK$8.10 |
| Beta | -0.97 |
| 1 Month Change | 52.05% |
| 3 Month Change | -11.44% |
| 1 Year Change | 12.01% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 6.33% |
Recent News & Updates
Shareholder Returns
| 2105 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -5.6% | -2.1% | 0.3% |
| 1Y | 12.0% | 110.2% | 32.2% |
Return vs Industry: 2105 underperformed the Hong Kong Biotechs industry which returned 110.2% over the past year.
Return vs Market: 2105 underperformed the Hong Kong Market which returned 32.2% over the past year.
Price Volatility
| 2105 volatility | |
|---|---|
| 2105 Average Weekly Movement | 12.5% |
| Biotechs Industry Average Movement | 8.4% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in HK Market | 14.4% |
| 10% least volatile stocks in HK Market | 3.0% |
Stable Share Price: 2105's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2105's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 84 | Chris Lu | www.laekna.com |
Laekna, Inc., an investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis in the People’s Republic of China, the United States of America, and South Korea. The company offers LAE002, an adenosine triphosphate competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer, and PD-1/PD-L1 drug-resistant solid tumors; LAE001, an androgen synthesis inhibitor that inhibits CYP17A1 and CYP11B2 to treat prostate cancer; LAE005, a ligand-blocking humanized anti-PD-L1 IgG4 antibody for the treatment of triple-negative breast cancer; and LAE102, a monoclonal antibody against ActRIIA to treat obesity. It also develops LAE109, LAE111, LAE112, LAE113, LAE122, LAE119, and LAE120 for the treatment of cancer; LAE118, a PI3Ka mutant-selective inhibitor; LAE103 for Sarcopenia; LAE123 to treat muscle and other disease indications; LAE104 and LAE105 for the treatment of liver fibrosis; and LAE106 to treat fibrosis.
Laekna, Inc. Fundamentals Summary
| 2105 fundamental statistics | |
|---|---|
| Market cap | HK$7.00b |
| Earnings (TTM) | -HK$264.42m |
| Revenue (TTM) | HK$5.09m |
Is 2105 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2105 income statement (TTM) | |
|---|---|
| Revenue | CN¥4.63m |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥4.63m |
| Other Expenses | CN¥244.85m |
| Earnings | -CN¥240.23m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.57 |
| Gross Margin | 100.00% |
| Net Profit Margin | -5,191.85% |
| Debt/Equity Ratio | 15.4% |
How did 2105 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/08 13:23 |
| End of Day Share Price | 2025/12/08 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Laekna, Inc. is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yaxin Liu | China International Capital Corporation Limited |
| Jiacheng Zhu | Citic Securities Co., Ltd. |
| Wai Ming Kong | DBS Bank Ltd |